Zobrazeno 1 - 10
of 1 166
pro vyhledávání: '"TKI resistance"'
Autor:
Weina Fan, Ying Xing, Shi Yan, Wei Liu, Jinfeng Ning, Fanglin Tian, Xin Wang, Yuning Zhan, Lixin Luo, Mengru Cao, Jian Huang, Li Cai
Publikováno v:
Cancer Cell International, Vol 24, Iss 1, Pp 1-19 (2024)
Abstract Background Lung adenocarcinoma (LUAD) patients have a dismal survival rate because of cancer metastasis and drug resistance. The study aims to identify the genes that concurrently modulate EMT, metastasis and EGFR-TKI resistance, and to inve
Externí odkaz:
https://doaj.org/article/aeee91a5a9284ceca2e6632d57eec117
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
Non-small cell lung cancer (NSCLC) is one of the most common malignancies in the world. EGFR tyrosine inhibitors are the preferred first-line treatment for patients with epidermal growth factor-cell receptor mutant (EGFR mutant) advanced NSCLC. Unfor
Externí odkaz:
https://doaj.org/article/c240e7fda61541daa0fbe059229966dc
Publikováno v:
Genes and Diseases, Vol 11, Iss 5, Pp 101150- (2024)
The advent of tyrosine kinase inhibitors (TKI) targeting BCR-ABL has drastically changed the treatment approach of chronic myeloid leukemia (CML), greatly prolonged the life of CML patients, and improved their prognosis. However, TKI resistance is st
Externí odkaz:
https://doaj.org/article/7cfec49cead04316911cebf15dc34f7c
Autor:
Zahidah Abu Seman, Fadly Ahid, Nor Rizan Kamaluddin, Ermi Neiza Mohd Sahid, Ezalia Esa, Siti Shahrum Muhamed Said, Norazlina Azman, Wan Khairull Dhalila Wan Mat, Julia Abdullah, Nurul Aqilah Ali, Mohd Khairul Nizam Mohd Khalid, Yuslina Mat Yusoff
Publikováno v:
BMC Research Notes, Vol 17, Iss 1, Pp 1-8 (2024)
Abstract Objective Mutational analysis of BCR::ABL1 kinase domain (KD) is a crucial component of clinical decision algorithms for chronic myeloid leukemia (CML) patients with failure or warning responses to tyrosine kinase inhibitor (TKI) therapy. Th
Externí odkaz:
https://doaj.org/article/ec23452a481e4309b0f21ac9bb3102d4
Autor:
Kan Jiang, Lin Wu, Xinlong Zheng, Yiquan Xu, Qian Miao, Xiaobin Zheng, Longfeng Zhang, Cheng Huang, Gen Lin
Publikováno v:
BMC Pulmonary Medicine, Vol 24, Iss 1, Pp 1-9 (2024)
Abstract Background Advanced lung adenocarcinoma patients often develop resistance to EGFR tyrosine kinase inhibitors (EGFR-TKIs), leaving uncertainties regarding subsequent treatment strategies. Although personalized therapy targeting individual acq
Externí odkaz:
https://doaj.org/article/cc9c753a114c4fb5838a49022edbbeb2
Autor:
Liantao Guo, Hong Cheng, Jianhua Liu, Weikang Shao, Lan Luo, Weijie Zheng, Shengrong Sun, Deguang Kong, Chuang Chen
Publikováno v:
BMC Medical Genomics, Vol 17, Iss 1, Pp 1-13 (2024)
Abstract Background Breast cancer is the second leading cause of cancer-related death in women, and drug resistance during treatment is a major challenge. However, the mechanisms underlying drug resistance are not fully understood. Here we applied wh
Externí odkaz:
https://doaj.org/article/714bc638cd6444fd891306ed71929bdb
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Boyang Shi, Ke An, Yueqin Wang, Yuhan Fei, Caixia Guo, Qiangfeng Cliff Zhang, Yun-Gui Yang, Xin Tian, Quancheng Kan
Publikováno v:
Genomics, Proteomics & Bioinformatics, Vol 21, Iss 4, Pp 850-865 (2023)
Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) positively affect the initial control of non-small cell lung cancer (NSCLC). Rapidly acquired resistance to EGFR-TKIs is a major hurdle in successful treatment. However, the mech
Externí odkaz:
https://doaj.org/article/c6e59523a7464d8bbc054b8c9402d7d1
Autor:
Juan Zhou, Xiangling Chu, Jing Zhao, Mengqing Xie, Jing Wu, Xin Yu, Yujia Fang, Yazhou Li, Xiyan Li, Chunxia Su
Publikováno v:
Biological Procedures Online, Vol 25, Iss 1, Pp 1-13 (2023)
Abstract Background Clinical studies suggest that immune checkpoint inhibitor (ICI) monotherapy has limited benefits in non-small cell lung cancer (NSCLC) patients after epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) failure. H
Externí odkaz:
https://doaj.org/article/67c780f444bc46258dd9398bbbe65e60
Autor:
Yen‐Ting Lin, Chao‐Chi Ho, Wei‐Hsun Hsu, Wei‐Yu Liao, Ching‐Yao Yang, Chong‐Jen Yu, Tzu‐Hsiu Tsai, James Chih‐Hsin Yang, Shang‐Gin Wu, Chia‐Lin Hsu, Min‐Shu Hsieh, Yen‐Lin Huang, Chia‐Ling Wu, Jin‐Yuan Shih
Publikováno v:
Cancer Medicine, Vol 13, Iss 1, Pp n/a-n/a (2024)
Abstract Introduction According to current International Association for the Study of Lung Cancer guideline, physicians may first use plasma cell‐free DNA (cfDNA) methods to identify epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor
Externí odkaz:
https://doaj.org/article/16337db479754d2fa1ffefc1d301d9fd